Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i

Go back to Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
Regeneron (NASDAQ: REGN) Delayed: 805.67 -1.81 (0.22%)
Previous Close $807.48    52 Week High $592.36 
Open $806.74    52 Week Low $325.35 
Day High $813.86    P/E 211.46 
Day Low $800.24    EPS $3.81 
Volume 581,048